Muscle atrophy prevention agent

Abstract

An object of the invention is to provide a novel technique for preventing muscle atrophy by directly promoting muscle synthesis or suppressing muscle degradation without through physical activity. An agent for preventing muscle atrophy containing a lactic acid bacterium having a muscle synthesis-promoting effect and/or a muscle degradation-suppressing effect, a treated product of the lactic acid bacterium or an extract thereof as an active ingredient in which the lactic acid bacterium having a muscle synthesis-promoting effect is Lactobacillus gasseri or the like and the lactic acid bacterium having a muscle degradation-suppressing effect is Lactobacillus reuteri or the like is provided.

1 . An agent for preventing muscle atrophy comprising a lactic acid bacterium having a muscle synthesis-promoting effect and/or a muscle degradation-suppressing effect, a treated product of the lactic acid bacterium or an extract thereof as an active ingredient,
 wherein the lactic acid bacterium having a muscle synthesis-promoting effect is any one kind or more selected from the group consisting of  Lactobacillus  gasseri,  Streptococcus thermophilus, Lactobacillus rhamnosus, Lactococcus lactis, Lactobacillus delbrueckii  and  Lactobacillus reuteri , and   the lactic acid bacterium having a muscle degradation-suppressing effect is any one kind or more selected from the group consisting of  Lactobacillus reuteri, Lactobacillus mucosae, Lactobacillus fermentum, Pediococcus acidilactici, Lactobacillus delbrueckii  and  Lactobacillus  gasseri.   
     
     
         2 . The agent for preventing muscle atrophy according to  claim 1 , wherein the lactic acid bacterium having a muscle synthesis-promoting effect is  Lactococcus lactis  subsp.  cremoris  or  Lactococcus lactis  subsp.  lactis.    
     
     
         3 . The agent for preventing muscle atrophy according to  claim 1 , wherein the lactic acid bacterium having a muscle synthesis-promoting effect is  Lactobacillus  gasseri strain SBT1848 (NITE BP-03075),  Streptococcus thermophilus  strain SBT1021A (FERM P-10658),  Lactococcus lactis  subsp.  cremoris  strain SBT1393 (NITE P-03278),  Lactobacillus rhamnosus  strain SBT2299 (NITE BP-02994),  Lactococcus lactis  subsp.  lactis  strain SBT2397 (NITE P-03080) or  Lactobacillus reuteri  strain SBT2970 (NITE BP-03282). 
     
     
         4 . The agent for preventing muscle atrophy according to  claim 1 , wherein the lactic acid bacterium having a muscle degradation-suppressing effect is  Lactobacillus reuteri  strain SBT2970 (NITE BP-03282),  Lactobacillus  mucosae strain SBT2958 (NITE P-02803),  Lactobacillus  mucosae strain SBT10038 (NITE P-03283),  Lactobacillus  mucosae strain SBT10043 (NITE BP-03187),  Lactobacillus fermentum  strain SBT1846 (NITE P-03279),  Lactobacillus fermentum  strain SBT1859 (NITE P-02996),  Pediococcus acidilactici  strain SBT3331 (NITE BP-02991) or  Lactobacillus  gasseri strain SBT1848 (NITE BP-03075). 
     
     
         5 . An agent for preventing muscle atrophy comprising a lactic acid bacterium having a muscle synthesis-promoting effect and a muscle degradation-suppressing effect, a treated product of the lactic acid bacterium or an extract thereof as an active ingredient. 
     
     
         6 . The agent for preventing muscle atrophy according to  claim 5 , wherein the lactic acid bacterium having a muscle synthesis-promoting effect and a muscle degradation-suppressing effect is  Lactobacillus delbrueckii, Lactobacillus  gasseri or  Lactobacillus reuteri.    
     
     
         7 . The agent for preventing muscle atrophy according to  claim 6 , wherein the lactic acid bacterium having a muscle synthesis-promoting effect and a muscle degradation-suppressing effect is  Lactobacillus delbrueckii  subsp.  lactis.    
     
     
         8 . The agent for preventing muscle atrophy according to  claim 6 , wherein the lactic acid bacterium having a muscle synthesis-promoting effect and a muscle degradation-suppressing effect is  Lactobacillus delbrueckii  subsp.  lactis  strain SBT1371 (NITE BP-03277),  Lactobacillus delbrueckii  subsp.  lactis  strain SBT2002 (NITE BP-03280),  Lactobacillus delbrueckii  subsp.  lactis  strain SBT2080 (NITE BP-03281),  Lactobacillus  gasseri strain SBT1848 (NITE BP-03075) or  Lactobacillus reuteri  strain SBT2970 (NITE BP-03282). 
     
     
         9 . A pharmaceutical product, a food or a drink, a food with a function claim, a food for a specified health use, a nutritional supplement, a supplement or feed for preventing muscle atrophy comprising the agent for preventing muscle atrophy according to  claim 1 . 
     
     
         10 .  Lactobacillus delbrueckii  subsp.  lactis  strain SBT1371 (NITE BP-03277),  Lactobacillus delbrueckii  subsp.  lactis  strain SBT2002 (NITE BP-03280),  Lactobacillus delbrueckii  subsp.  lactis  strain SBT2080 (NITE BP-03281),  Lactococcus lactis  subsp.  cremoris  strain SBT1393 (NITE P-03278),  Lactobacillus reuteri  strain SBT2970 (NITE BP-03282),  Lactobacillus  mucosae strain SBT10038 (NITE P-03283) and  Lactobacillus fermentum  strain SBT1846 (NITE P-03279) which are novel lactic acid bacteria.